Literature DB >> 22015573

Heat shock protein expression in canine osteosarcoma.

Mariarita Romanucci1, Giuliana D'Amato, Daniela Malatesta, Laura Bongiovanni, Chiara Palmieri, Andrea Ciccarelli, Paolo Buracco, Emanuela Morello, Lorella Maniscalco, Raffaella De Maria, Marina Martano, Leonardo Della Salda.   

Abstract

Abnormal levels of heat shock proteins have been observed in a number of human neoplasms and demonstrate prognostic, predictive and therapeutic implications. Since osteosarcoma (OSA) in dogs provides an important model for the same disease in humans, the aim of this study was to evaluate the immunohistochemical expression of Hsp27, Hsp72, Hsp73 and Hsp90 in 18 samples of canine appendicular OSA, in relation to histological grade and overall survival (OS), in order to investigate their potential prognostic, predictive and/or therapeutic value. A semiquantitative method was used for the analysis of the results. Hsp27, Hsp73 and Hsp90 showed a variably intense, cytoplasmic and nuclear immunoreactivity that was not associated with histological type or grade. On the other hand, a high percentage of Hsp72 immunostaining was significantly associated with grade III (P < 0.01) and a lack of immunolabelling was significantly correlated to a longer OS (P = 0.006). Neoplastic emboli were occasionally positive for Hsp27, faintly immunoreactive for Hsp72 and intensely immunolabelled by Hsp73 and Hsp90. In conclusion, absence of Hsp72 immunosignal appears to be associated with a favourable prognosis whilst the widespread Hsp90 immunoreactivity detected in all tumour cases as well as in neoplastic emboli, suggests this protein could be targeted in the therapy of canine OSA, and likewise in its human counterpart.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22015573      PMCID: PMC3227845          DOI: 10.1007/s12192-011-0294-2

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


  32 in total

1.  Expression and distribution of HSP27 in response to G418 in different human breast cancer cell lines.

Authors:  Lu Qian; Zhiyi Zhang; Ming Shi; Ming Yu; Meiru Hu; Qing Xia; Beifen Shen; Ning Guo
Journal:  Histochem Cell Biol       Date:  2006-05-30       Impact factor: 4.304

2.  Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.

Authors:  Benjamin Ory; Marie-Françoise Heymann; Akira Kamijo; François Gouin; Dominique Heymann; Françoise Redini
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

3.  Of humans and canines: a comparative evaluation of heat shock and apoptosis-associated proteins in mammary tumors.

Authors:  Ramasamy Kumaraguruparan; Devarajan Karunagaran; Chidambaram Balachandran; Baktavachalam Murali Manohar; Siddavaram Nagini
Journal:  Clin Chim Acta       Date:  2005-09-19       Impact factor: 3.786

Review 4.  Comparative biology of human and canine osteosarcoma.

Authors:  F Mueller; B Fuchs; B Kaser-Hotz
Journal:  Anticancer Res       Date:  2007 Jan-Feb       Impact factor: 2.480

5.  Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma.

Authors:  Ruthanne Chun; Laura D Garrett; Carolyn Henry; Michelle Wall; Annette Smith; Nicole M Azene
Journal:  J Am Anim Hosp Assoc       Date:  2005 Nov-Dec       Impact factor: 1.023

Review 6.  Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications.

Authors:  Daniel R Ciocca; Stuart K Calderwood
Journal:  Cell Stress Chaperones       Date:  2005       Impact factor: 3.667

Review 7.  Heat shock proteins in cancer: chaperones of tumorigenesis.

Authors:  Stuart K Calderwood; Md Abdul Khaleque; Douglas B Sawyer; Daniel R Ciocca
Journal:  Trends Biochem Sci       Date:  2006-02-17       Impact factor: 13.807

8.  Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.

Authors:  Rochelle Bagatell; Lia Gore; Merrill J Egorin; Richard Ho; Glenn Heller; Nichole Boucher; Eleanor G Zuhowski; James A Whitlock; Stephen P Hunger; Aru Narendran; Howard M Katzenstein; Robert J Arceci; Jessica Boklan; Cynthia E Herzog; Luke Whitesell; S Percy Ivy; Tanya M Trippett
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

9.  Zoledronic acid inhibits osteosarcoma growth in an orthotopic model.

Authors:  Crispin R Dass; Peter F M Choong
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

10.  Heat shock protein expression in canine malignant mammary tumours.

Authors:  Mariarita Romanucci; Alessia Marinelli; Giuseppe Sarli; Leonardo Della Salda
Journal:  BMC Cancer       Date:  2006-06-27       Impact factor: 4.430

View more
  4 in total

1.  Targeting HSP70 and GRP78 in canine osteosarcoma cells in combination with doxorubicin chemotherapy.

Authors:  Jonathan Asling; Jodi Morrison; Anthony J Mutsaers
Journal:  Cell Stress Chaperones       Date:  2016-09-08       Impact factor: 3.667

2.  Heat shock protein expression analysis in canine osteosarcoma reveals HSP60 as a potentially relevant therapeutic target.

Authors:  Gayathri T Selvarajah; Floor A S Bonestroo; Jolle Kirpensteijn; Marja J L Kik; Ruurd van der Zee; Willem van Eden; Elpetra P M Timmermans-Sprang; Adri Slob; Jan A Mol
Journal:  Cell Stress Chaperones       Date:  2013-03-06       Impact factor: 3.667

3.  Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, β-catenin, p53, caspase 3) in canine appendicular osteosarcoma.

Authors:  Laura Bongiovanni; Francesca Mazzocchetti; Daniela Malatesta; Mariarita Romanucci; Andrea Ciccarelli; Paolo Buracco; Raffaella De Maria; Chiara Palmieri; Marina Martano; Emanuela Morello; Lorella Maniscalco; Leonardo Della Salda
Journal:  BMC Vet Res       Date:  2012-06-11       Impact factor: 2.741

Review 4.  Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues.

Authors:  Morgane Lallier; Louise Marchandet; Brice Moukengue; Celine Charrier; Marc Baud'huin; Franck Verrecchia; Benjamin Ory; François Lamoureux
Journal:  Cells       Date:  2021-03-30       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.